Cassava Sciences(SAVA)2025-03-03 12:40Financial Position - Unaudited cash and cash equivalents balance as of December 31, 2024 was approximately 0.4 million related to severance payments for the workforce reduction[8] - Workforce reduction expected to be completed, and associated costs incurred, during the first quarter of 2025[8] Clinical Trials and Study Results - Phase 3 ReThink-ALZ study of simufilam in mild-to-moderate Alzheimer's disease did not meet prespecified co-primary endpoints[6] - The company decided to discontinue its Phase 3 ReFocus-ALZ study and its open-label extension study[6] - The company plans to share detailed study results at a future medical meeting[10] Forward-Looking Statements and Risks - Forward-looking statements include risks related to clinical study timelines, unexpected costs, and drug development uncertainties[11] Regulatory and Reporting - The company's press release dated January 7, 2025, is attached as Exhibit 99.1[12] - The report is signed by Eric J. Schoen, Chief Financial Officer, on January 7, 2025[15]